DUBLIN–(BUSINESS WIRE)–Oct 13, 2020–
The “Encephalomyelitis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Encephalomyelitis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalomyelitis (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Topics Covered:
- Encephalomyelitis – Overview
- Encephalomyelitis – Therapeutics Development
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Encephalomyelitis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Encephalomyelitis – Companies Involved in Therapeutics Development
- AIM ImmunoTech Inc
- Biovista Inc
- Cortene Inc
- Inflazome Ltd
- K-Pax Pharmaceuticals Inc
- Orion BioScience Inc
- Philogen SpA
Encephalomyelitis – Drug Profiles
- CT-38 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders – Drug Profile
- JM-4 – Drug Profile
- KPAX-002 – Drug Profile
- MCC-950 – Drug Profile
Encephalomyelitis – Dormant Projects
- Encephalomyelitis – Product Development Milestones
Featured News & Press Releases
- Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
List of Tables
- Number of Products under Development for Encephalomyelitis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Encephalomyelitis – Pipeline by AIM ImmunoTech Inc, H2 2020
- Encephalomyelitis – Pipeline by Biovista Inc, H2 2020
- Encephalomyelitis – Pipeline by Cortene Inc, H2 2020
- Encephalomyelitis – Pipeline by Inflazome Ltd, H2 2020
- Encephalomyelitis – Pipeline by K-Pax Pharmaceuticals Inc, H2 2020
- Encephalomyelitis – Pipeline by Orion BioScience Inc, H2 2020
- Encephalomyelitis – Pipeline by Philogen SpA, H2 2020
- Encephalomyelitis – Dormant Projects, H2 2020
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pzk6rg
View source version on businesswire.com:https://www.businesswire.com/news/home/20201013005831/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 10/13/2020 10:53 AM/DISC: 10/13/2020 10:53 AM